New studies change how we think about lithium and weight gain, and updates on lumateperone, lavender, and esketamine in depression. 

We count down the top 10 research updates of the past year with a focus on treatment resistant depression and benzo withdrawal.

KarXT (Cobenfy) is the first antipsychotic that doesn’t block dopamine. We trace the origins of this new drug to a South Asian herb used for over 5,000 years, up to the three EMERGENT trials that led to its FDA approval.

Listen to the full text of the issue read aloud by Gregory Malzberg, MD. It’s official. The DEA has conscripted all licensed clinicians to prescribe buprenorphine. Noah Capurso shows us how to do it. Meanwhile, Europe warns of post-SSRI sexual dysfunction, aerobic exercise enhances PTSD therapy, and new strategies for antipsychotic-induced hyperprolactinemia.